For many academics currently working from home, writing will be a secondary consideration, or even impossible. However, for others writing can be an essential way to maintain a sense of stability and to meaningfully respond to the current situation.
Earlier this year, Alzheimer’s Research UK offered dementia researchers in the early stages of their career a chance to sit in on a meeting of our Grant Review Board. Dr Lauren Walker took the opportunity…
Two science communicators explain how researchers who present themselves as curious, fallible humans might be perceived as more authentic in this post shared from Nature Careers.
Respect for what you and your colleagues bring to the table is vital to successful integration, says Melissa T. Miller in her blog for Nature Careers
Blog shared from Hilary Evans for Alzheimer’s Research UK – New report published by Alzheimer’s Research UK shines a light on the UK’s attitudes towards dementia and research
Alzheimer’s Society Annual Review highlights what Alzheimer’s Society research has been working and achieved in the last year
Academic writing is often criticised for its tendency to be arid and unengaging, but what makes a paper interesting? Find out in this great blog by Dr Manuel Goyanes, shared from the LSE Impact Blog
Blog from Joshua Bauermeister for DPUK, providing an insight into a key job that makes it possible for researchers to compare data across different cohorts in the Data Portal.
Missing documentation and obsolete environments force participants in the Ten Years Reproducibility Challenge to get creative – take a look at this article by
Is your desk a hot mess right now? Dr Linda Devereux can relate. In this post she shares the touching story of cleaning her office after the PhD was finished and the unexpected difficulty of the clearing out process.
Springer Nature Storytellers hosted an event at Berlin Science Week in which five researchers on the front lines of discovery shared true stories about life behind the science.
At the virtual AAT-AD/PD Focus meeting, clinicians and funders involved in the DIAN-TU Trial fired up their home computers to discuss results from the first DIAN-TU treatment and prevention trial of Eli Lilly’s monoclonal antibody solanezumab, and Roche’s gantenerumab.
LSE Impact Blog
Dementia Researcher
Nature Careers Blog
Alz Forum